Summary
Boston Scientific Corporation (BSX) announced on August 8, 2013, the pricing of a public offering of senior notes totaling $1.05 billion. This offering comprises $600 million in 2.650% notes due in 2018 and $450 million in 4.125% notes due in 2023. The company intends to use the proceeds from this new debt issuance, along with borrowings from its term loan facility, to redeem a substantial portion of its outstanding senior notes: $600 million of 5.450% notes due in 2014 and $850 million of 4.500% notes due in 2015. This move signals a proactive debt management strategy, aiming to refinance existing debt at potentially lower interest rates and extend maturity profiles. The transaction is expected to close on August 13, 2013, subject to customary conditions. The primary objective is to reduce interest expenses and improve the company's debt structure. Any remaining proceeds not used for debt redemption will be allocated for general corporate purposes. Investors should note the forward-looking nature of this announcement, with actual results potentially differing due to various market and business risks outlined by the company.
Key Highlights
- 1Boston Scientific priced a $1.05 billion senior notes offering on August 8, 2013.
- 2The offering includes $600 million of 2.650% notes due 2018 and $450 million of 4.125% notes due 2023.
- 3Proceeds will be used to redeem $600 million of 5.450% notes due 2014.
- 4Proceeds will also be used to redeem $850 million of 4.500% notes due 2015.
- 5The transaction is expected to close on August 13, 2013.
- 6The company aims to improve its debt structure and potentially lower interest expenses.
- 7Remaining proceeds may be used for general corporate purposes.